RE: WTR report16 Jun 2026 16:08
We know there are two data packages. The first part of Package 1 has been delivered but not yet publicly communicated.
NIDA’s focus on metabolites required additional toxicology studies, which are presumably bundled into Package 2.
Meanwhile, management previously noted the need for stronger IP protection, an area they have likely been addressing in the background.
Official communication on these fronts has been perfunctory, suggesting updates are either being intentionally withheld or delayed to align with the granting of the new patent.
As for the share price? Better ask a crystal ball.